

In the Claims:

Claims 1 to 22 (cancelled).

Claim 23. (currently amended) A lipopeptide comprising at least one auxiliary T epitope, at least one CTL epitope and one lipid moiety wherein the lipid moiety consists of a unbranched or branched, unsaturated or saturated, chain derived from fatty acids of 10 to 20 carbon atoms:

the at least one CTL epitope consists of a CTL epitope of a HIV protein;
and wherein

the lipid moiety and the epitopes are separated by hydrophilic aminoacid spacer chain selected from the group consisting of GLY ARG and ARG GLY ARG having a length of 1 to 10 aminoacids, said aminoacid residues being independently selected from glycine, arginine, glutamic acid, aspartic acid and cysteine; or

two distinct epitopes are separated by a hydrophilic aminoacid spacer chain selected from the group consisting of GLY ARG and ARG GLY ARG having a length of 1 to 10 aminoacids, said aminoacid residues being independently selected from glycine, arginine, glutamic acid, aspartic acid and cysteine; or

both the lipid moiety and the epitopes on the one hand, and the epitopes, on the other hand, are separated by ~~an~~ at least one aminoacid spacer chain selected from the group consisting of GLY ARG and ARG GLY ARG.

Claim 24 to 27(cancelled).

Claim 28 (previously presented) A lipopeptide of Claim 23 wherein the amino acid spacer chain comprises an alkyl functionalized by a thiol and non-peptide bonds.

Claim 29 (previously presented) A lipopeptide of Claim 23 wherein the amino acid spacer chain comprises a member selected from the group consisting of thiazolidine, oxime and hydrazone.

Claim 30 (previously presented) A lipopeptide of Claim 23 comprised of a lipid – a first spacer – an auxiliary T eopeptide – a second spacer – a CTL epitope.

Claim 31 (previously presented) A lipopeptide of Claim 23 comprised of a lipid – a first spacer – auxiliary T epitope – a second spacer – a first CTL epitope – a second CTL epitope.

Claims 32 - 34 (cancelled).

Claim 35 (previously presented) A lipopeptide of Claim 23 wherein the lipid is a moiety selected from the group consisting of palmitic acid, oleic acid, linoleic acid, 2-amino hexadecanoic acid, pimelautide and trimexautide.

Claim 36 (previously presented) A lipopeptide of Claim 23 wherein the non-lipid portion is comprised of 15 to 100 amino acids.

Claim 37 (previously presented) A lipopeptide of Claim 23 wherein the auxiliary T epitope is a multivalent epitope.

Claim 38 (previously presented) A lipopeptide of Claim 23 wherein the auxiliary T epitope is the 830-843 peptide of tetanus toxin with the sequence QYIKANSKFIGITE.

Claim 39 (previously presented) A lipopeptide of Claim 23 wherein the auxiliary T epitope is haemagglutinin epitope or PADRE epitope.

Claim 40 (cancelled).

Claim 41 (previously presented) A method of inducing a specific immune response against HIV in a warm-blooded animal comprising administering to a warm-blooded animal an amount of a lipopeptide of Claim 23 sufficient to induce a specific immune response.

Claim 42 (cancelled).

Claim 43 (previously presented) A vaccine comprising an immune inducing effective amount of at least one lipopeptide of Claim 23.